Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy
- PMID: 17001071
- DOI: 10.1200/JCO.2006.05.9212
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy
Abstract
Purpose: This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate.
Patients and methods: This prospective study evaluated the impact of second-line zoledronic acid on pain, quality of life, and markers of bone turnover (for example, urinary N-telopeptide [NTX]). Patients received monthly zoledronic acid (4 mg) for 3 months. Study evaluations were made weekly during the first month and again at week 8. No changes in chemotherapy or endocrine therapy were allowed in the month before or after commencing study treatment.
Results: Thirty-one women completed this study. By week 8, patients had experienced significant improvements in pain control (P < .001). There was a downward trend in urinary NTX levels over the same time period (P = .008). Overall, there was a trend towards a positive correlation between improvement in pain control and reduction in week one urinary NTX relative to baseline (Spearman's rho r = 0.27; P = .15).
Conclusion: This is the first study to demonstrate that patients with either progressive bone metastases or SREs while on clodronate or pamidronate can have relevant palliative benefits with a switch to the more potent bisphosphonate zoledronic acid. This is reflected by significant improvements in pain control and bone turnover markers. If confirmed in randomized trials, these findings have major implications to the use of bisphosphonates in both the metastatic and adjuvant settings.
Similar articles
-
Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.Oncologist. 2006 Jul-Aug;11(7):841-8. doi: 10.1634/theoncologist.11-7-841. Oncologist. 2006. PMID: 16880243 Clinical Trial.
-
Optimal management of metastatic bone disease.Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7. doi: 10.1016/j.ejon.2007.07.003. Epub 2007 Sep 4. Eur J Oncol Nurs. 2007. PMID: 17804294 Review.
-
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.Cancer J. 2001 Sep-Oct;7(5):377-87. Cancer J. 2001. PMID: 11693896 Clinical Trial.
-
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.Breast Cancer Res Treat. 2008 Mar;108(1):79-85. doi: 10.1007/s10549-007-9583-y. Epub 2007 May 2. Breast Cancer Res Treat. 2008. PMID: 17473981 Clinical Trial.
-
Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.Cancer Treat Rev. 2005;31 Suppl 3:19-25. doi: 10.1016/j.ctrv.2005.09.004. Epub 2005 Oct 14. Cancer Treat Rev. 2005. PMID: 16229955 Review.
Cited by
-
A randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis.Indian J Palliat Care. 2011 Sep;17(3):210-8. doi: 10.4103/0973-1075.92338. Indian J Palliat Care. 2011. PMID: 22346045 Free PMC article.
-
Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review.Support Care Cancer. 2007 Nov;15(11):1243. doi: 10.1007/s00520-007-0244-9. Epub 2007 Mar 29. Support Care Cancer. 2007. PMID: 17393190 Review.
-
Effect of bisphosphonates on pain and quality of life in patients with bone metastases.Nat Clin Pract Oncol. 2009 Mar;6(3):163-74. doi: 10.1038/ncponc1323. Epub 2009 Feb 3. Nat Clin Pract Oncol. 2009. PMID: 19190592 Review.
-
Zoledronic acid induces ferroptosis by upregulating POR in osteosarcoma.Med Oncol. 2023 Apr 10;40(5):141. doi: 10.1007/s12032-023-01988-w. Med Oncol. 2023. PMID: 37036615
-
Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases.J Clin Med. 2013 Aug 19;2(3):67-88. doi: 10.3390/jcm2030067. J Clin Med. 2013. PMID: 26237063 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical